Pathology Assessments of Multiple Organs in Fatal COVID-19 in Intensive Care Unit vs. Non-intensive Care Unit Patients.
ARDS
COVID-19
ICU
SARS-CoV-2
lung pathology
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
12
2021
accepted:
29
03
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
14
5
2022
Statut:
epublish
Résumé
The objective of the present study was to provide a detailed histopathological description of fatal coronavirus disease 2019 (COVID 19), and compare the lesions in Intensive Care Unit (ICU) and non-ICU patients. In this prospective study we included adult patients who died in hospital after presenting with confirmed COVID-19. Multiorgan biopsies were performed. Data generated with light microscopy, transmission electron microscopy (TEM) and RT-PCR assays were reviewed. 20 patients were enrolled in the study and the main pulmonary finding was alveolar damage, which was focal in 11 patients and diffuse in 8 patients. Chronic fibrotic and inflammatory lesions were observed in 18 cases, with acute inflammatory lesions in 12 cases. Diffuse lesions, collapsed alveoli and dystrophic pneumocytes were more frequent in the ICU group (62.5%, vs. 25%; 63%, vs. 55%; 87.5%, vs. 54%). Acute lesions (82%, vs. 37.5%; Lung injury was different in ICU and non-ICU patients. Extrapulmonary damage consisting in kidney and myocardial injury were more frequent in ICU patients. Our TEM experiments provided the first description of SARS-CoV-2-induced DMVs in kidney biopsy samples-a sign of intense viral replication in this organ.
Identifiants
pubmed: 35547201
doi: 10.3389/fmed.2022.837258
pmc: PMC9081791
doi:
Types de publication
Journal Article
Langues
eng
Pagination
837258Informations de copyright
Copyright © 2022 Zerbib, Guilain, Eymieux, Uzbekov, Castelain, Blanchard, François, Chatelain, Brault, Maizel, Roingeard and Slama.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Chest. 2021 Jan;159(1):73-84
pubmed: 33038391
Curr Opin Crit Care. 2020 Feb;26(1):59-65
pubmed: 31815775
J Pathol. 2004 Jun;203(2):622-30
pubmed: 15141376
Trends Microbiol. 2020 Dec;28(12):1022-1033
pubmed: 32536523
Am J Respir Crit Care Med. 2013 Apr 1;187(7):761-7
pubmed: 23370917
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Pathol. 2020 Dec;252(4):346-357
pubmed: 32918747
Intensive Care Med. 2020 Jun;46(6):1124-1126
pubmed: 32328726
Cell Mol Life Sci. 2021 Apr;78(7):3565-3576
pubmed: 33449149
Lancet. 2020 Aug 1;396(10247):320-332
pubmed: 32682491
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Sci Rep. 2021 Feb 10;11(1):3515
pubmed: 33568700
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Clin Microbiol. 2007 Feb;45(2):421-5
pubmed: 17166966
Travel Med Infect Dis. 2020 Mar - Apr;34:101623
pubmed: 32179124
Intensive Care Med. 2021 Jan;47(1):60-73
pubmed: 33211135
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Hum Pathol. 2021 Mar;109:59-68
pubmed: 33307078
Lancet. 2020 May 30;395(10238):e99
pubmed: 32442529
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1560-1564
pubmed: 32348678
Kidney Int. 2020 Jul;98(1):219-227
pubmed: 32327202
Lancet Respir Med. 2020 Jul;8(7):681-686
pubmed: 32473124
Cell Microbiol. 2015 Jan;17(1):45-50
pubmed: 25287059
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
J Am Soc Nephrol. 2020 Sep;31(9):2223-2224
pubmed: 32651224
Mod Pathol. 2020 Jun;33(6):1007-1014
pubmed: 32291399
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059